Поисковый запрос: <.>S=ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ СПЕЦИФИЧЕСКИЙ АНТИГЕН -- Prostate-Specific Antigen<.> |
Общее количество найденных документов : 106
Показаны документы с 1 по 20 |
|
1.
| Yao Siu-Long Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer./ Siu-Long Yao, G. Lu-Yao // JOURNAL of UROLOGY. -New York, 2001. т.Vol.166,N N3.-С.861--865
|
2.
| Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy./T.M. Soergel, M.O. Koch, R.S. Foster et al. // JOURNAL of UROLOGY. -New York, 2001. т.Vol.166,N N6.-С.2198-2201
|
3.
| Мечев Д.С. Простатический специфический антиген в диагностике рака предстательной железы/Д.С. Мечев, О.В. Щербина // Український медичний часопис. -Київ, 2002,N N4.-С.101-106
|
4.
| Медведев В.Л. Диагностическое значение сывороточного и тканевого простатического специфического антигена при раке предстательной железы/В.Л. Медведев // Военно-медицинский журнал. -М, 2004. т.Том325,N N2.-С.50-54
|
5.
| Kobayashi T. Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate./T. Kobayashi, T. Kamato, Y. Isogawa // JOURNAL of UROLOGY. -New York, 2003. т.Vol.169,N N1.-С.121-124
|
6.
| Han M. Biochemical ( Prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer/M. Han, A.W. Partin, M. Zahurak // JOURNAL of UROLOGY. -New York, 2003. т.Vol.169,N N2.-С.517-523
|
7.
| Freedland S.J. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy : results from the search data base/S.J. Freedland, C.J. Kane, J.C. Presti // JOURNAL of UROLOGY. -New York, 2003. т.Vol.169,N N3.-С.969-973
|
8.
| Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in hispanic-american and white men/J.S. Lam, K. Cheung, M.C. Benson, Goluboff E.T. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N2 pt.1 of 2.-С.451-456
|
9.
| Щербина О.В. Роль простатического специфического анти гена в диагностике рака предстательной железы/О.В. Щербина, В.С. Сакало, С.С. Замятин // Лабораторна діагностика. -київ, 2006,N N1.-С.21-26.
|
10.
| Опухолевые маркеры в диагностике рака предстательной железы и мониторинге больных/О.В. Щербина, В.С. Сакало, И.А. Клименко и др // Здоровье мужчины, 2006,N N 1.-С.138-143.
|
11.
| Петров С.Б. Диагностика локализованного рака предстательной железы/С.Б. Петров, П.В. Харченко // Урология, 2005,N № 1.-С.19-22.
|
12.
| Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 NG / ML/W.J. Catalona, G. Bartsch, H.G. Rittenhouse et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6, pt.1 of 2.-С.2181 - 2185
|
13.
| Overview Consensus Statement: third international conference on innovation and challenges in prostate cancer: prevention,detection and treatment /P.R. Carroll, D.A. Benaron , G. Blackledge et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6 pt.2 of 2 .-С.S3 - S5
|
14.
| Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from Ca PSURE) /M.R. Cooperberg, D.P. Lubeck, S.S.Mehta, P.R.Carroll // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6 pt.2 of 2 .-С.S21 - S27
|
15.
| Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era/A.V. D'amico , K. Cote , M. Loffredo et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6 pt.2 of 2 .-С.S42-47
|
16.
| Clinical use of monoclonal antibody Hu J591 therapy: targeting prostate specific membrane antigen/D.M. Nanus, M.I. Milowsky, L. Kostakoglu et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6 pt.2 of 2 .-С.S84 - S89
|
17.
| Prostatic zinc and prostate specific antigen: an experimental evaluation of their combined diagnostic value /D. Vartsky, S. Shilstein, A. Bercovich et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6, pt.1 of 2.-С.2258 - 2262
|
18.
| Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies/A. Haese, M. Graefen, N. Steuber // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6, pt.1 of 2.-С.2269 - 2273
|
19.
| Can prostate specific antigen derivatives and pathological parameters predict significant chenge in expectant management criteria for prostate cancer?/M.A. Khan, H.B. Carter, J.I. Epstein et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6, pt.1 of 2.-С.2274 - 2278
|
20.
| Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE /M.V. Meng, E.P. Elkin, S.R. Harlan et al. // JOURNAL of UROLOGY. -New York, 2003. т.Vol.170,N N6, pt.1 of 2.-С.2279 - 2283
|
|
|
|
Періодичних видань
Стандартный